证券代码：688596 证券简称：正帆科技 公告编号：2024-072 上海正帆科技股份有限公司 关于 2021 年第二期股票期权激励计划第三个行权期 行权条件成就的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●股票期权拟行权数量：3,134,800份 ●行权股票来源：公司向激励对象定向发行公司A股普通股 上海正帆科技股份有限公司（以下简称"公司"）于2024年12月3日召开第 四届董事会第七次会议和第四届监事会第七次会议，审议通过了《关于公司2021 年第二期股票期权激励计划第三个行权期行权条件成就的议案》。根据公司《2021 年第二期股票期权激励计划（草案）》的相关规定，2021年第二期股票期权激励 计划第三个行权期的行权条件已经成就，现将相关事项公告如下： 一、股权激励计划批准及实施情况 （一）股票期权激励计划方案及履行程序 公司于2021年11月制定并实施了《上海正帆科技股份有限公司2021年第二期 股票期权激励计划（草案）》，合计向激励对象授予972.00万份股票期权。其中 首次授予部分 ...

证券代码：688596 证券简称：正帆科技 公告编号：2024-071 上海正帆科技股份有限公司 关于收购控股子公司少数股东股权暨关联交易的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ●由于公司实际控制人之一 CUI RONG（崔荣）持有本次交易一方香港风舸 有限公司（以下简称"香港风舸"）100%股权并担任其董事，根据《上海证券交 易所科创板股票上市规则》《上市公司重大资产重组管理办法》等相关规定，本 次交易构成关联交易，但不构成重大资产重组，不存在重大法律障碍。 ●本事项已经公司第四届董事会独立董事第二次专门会议、第四届董事会第 七次会议及第四届监事会第七次会议审议通过，关联董事 YU DONG LEI（俞东 雷）和 CUI RONG（崔荣）回避表决，本次关联交易事项属于董事会决策权限， 无需提交股东大会审议。 一、 关联交易概述 正帆科技作为泛半导体产业制程关键系统与装备的供应商，鸿舸半导体系公 司控股子公司，主要从事泛半导体工艺设备模块与子系统业务，基于对其价值的 高度认可和未来发展的良好预期，以及综合 ...

证券简称：正帆科技 证券代码：688596 上海正帆科技股份有限公司 第二期员工持股计划 （草案）摘要 二〇二四年十二月 声明 本公司及董事会全体成员保证本员工持股计划不存在虚假记载、误导性陈述 或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 风险提示 1、本员工持股计划须经公司股东大会批准后方可实施，后续能否获得公司 股东大会批准尚存在不确定性； 2、本员工持股计划的具体实施方案属初步方案，能否完成实施，存在不确 定性； 3、员工遵循依法合规、自愿参与、风险自担原则，本员工持股计划存在不 成立或者低于预计规模的风险； 4、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 -2- 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 1、《上海正帆科技股份有限公司第二期员工持股计划（草案）》系公司依 据《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司实施员 工持股计划试点的指导意见》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法规、规章、规范性文件和《上海正帆科 技股份有限公司章程》等规定制定。 2、本员工 ...

上海正帆科技股份有限公司 关于 2021 年第二期股票期权激励计划第二个行权期 自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次行权数量： 上海正帆科技股份有限公司（ 以下简称"公司"）2021 年第二期股票 期权激励计划第二个行权期可行权数量为 3,042,600 股，行权期为 2023 年 12 月 22 日至 2024 年 12 月 2 日（行权日须为交易日）。截至 2024 年 11 月 19 日，累计行权并完成股份过户登记数量为 3,042,600 股，占本次可行权总量 的 100%。 证券代码：688596 证券简称：正帆科技 公告编号：2024-064 本次行权股票上市流通时间： 公司本次行权采用自主行权模式，激励对象行权所得股票于行权日（T 日）后的第一个交易日（T+1 日）到达股票账户，并于第二个交易日（T+2 日）上市交易。 一、本次股票期权行权的决策程序及行权情况 1、本激励计划的决策程序及信息披露情况 公司于 2021 年 11 月制定并实施了《上海正 ...

季报点评|专用设备 证券研究报告 正帆科技（688596.SH） 业绩符合预期,OPEX 业务进展明显 核心观点: ● ● ● 7.35、9.30 亿元,EPS 分别为 1.90、2.55、3.23元/股,根据可比公司 的估值情况,结合公司在设备行业积极开拓,以及在气体等 OPEX 等 领域进展较为迅速,因此给予公司 2024年24x 的 PE 估值,对应合理 价值 45.55元/股,维持"买入"评级。 风险提示。下游扩产不及预期;新业务开拓不及预期;应收账款无法收 回的风险。 ● 盈利预测: | --- | --- | --- | --- | --- | --- | |------------------------------------------------------|------------|------------|------------|------------|------------| | | | | | | | | | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入(百万元) 增长单 (%) | 2705 47.3% | 3835 41.8 ...

正帆科技 20241114 摘要 • 2024 年前三季度，公司实现营业收入 35 亿元，同比增长 45%；规模净利 润 3.3 亿元，同比增长 23%；扣非归母净利润 3.1 亿元，同比增长 55%。 第三季度公司实现营业收入 16.5 亿元，同比增长 55%；规模净利润 2.3 亿元，同比增长 88%；扣非归母净利润 1.95 亿元，同比增长 56%。 • 公司 IC 行业收入占比接近 60%，已成为集成电路产业相关领域的第一梯 队供应商。前三季度税前扣非利润率为 9.7%，较去年同期增加 0.5 个百 分点。 • 公司业务中来自 IC 行业的业务规模快速扩大，占比超过 50%，其中先进 制程业务占比超过 70%。光伏行业波动未对整体业绩产生重大影响。 • 公司在半导体检测和工艺设备领域进行了战略投资，跨赛道战略逐步落地， 新能源、新材料等行业的业务占比已超过 10%。 • 公司不断提升经营质量，费用逐年下降，净资产收益率稳健提升。前三季 度应收款项合计 21.7 亿，同比增加 25%，增幅远低于同期营业收入增幅。 第三季度经营性现金流 2.4 亿元，同比增长 107%，回款力度大幅提升。 • 公司长期实 ...

上海正帆科技股份有限公司 关于召开2024年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 证券代码：688596 证券简称：正帆科技 公告编号：2024-063 三、参加嘉宾 董事长：YU DONG LEI（俞东雷）先生 独立董事：余显财先生 副总经理兼财务总监兼董事会秘书：ZHENG HONGLIANG（郑鸿亮）先生 （如遇特殊情况，参会人员可能进行调整）。 四、投资者参加方式 投资者可于 2024 年 11 月 14 日（星期 四 ） 15:00-16:00 通过网址 https://eseb.cn/1jd2AkptKSc 或使用微信扫一扫以下小程序码即可进入参与 互动交流。投资者可于 2024 年 11 月 14 日前进行会前提问，公司将通过本次业 绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 上海正帆科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日 在上海证券交易所网站（www.sse.com.cn）发布了 20 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company reported a revenue of 3.501 billion RMB in Q3 2024, representing a year-on-year increase of 45.23%. The net profit attributable to shareholders was 332 million RMB, up 22.58% year-on-year [3]. - In Q3 2024, the company achieved a single-quarter revenue of 1.649 billion RMB, a 54.63% increase year-on-year, with a net profit of 227 million RMB, reflecting an 87.72% year-on-year growth [3]. - The company has a robust order backlog, with non-equipment orders increasing significantly, indicating a shift in product and order structure [4]. Summary by Sections Revenue and Profit Performance - For the first three quarters of 2024, the company achieved a total revenue of 3.501 billion RMB, with a net profit of 332 million RMB, marking significant growth compared to the previous year [3]. - The third quarter alone saw a revenue of 1.649 billion RMB and a net profit of 227 million RMB, showcasing strong quarterly performance [3]. Business Operations - The company has a sufficient order backlog, with non-equipment business contracts increasing by 83% year-on-year, indicating a rapid growth in this segment [4]. - The operating cash flow for Q3 2024 was 240 million RMB, a 107% increase year-on-year, demonstrating improved cash collection efficiency [4]. Capital Expansion and Share Buyback - The company plans to issue convertible bonds to raise up to 1.102 billion RMB for expanding electronic materials production and developing biopharmaceutical equipment [5]. - A share buyback of 1,615,286 shares was completed, representing 0.56% of the total share capital, reflecting the company's confidence in long-term growth [5]. Profit Forecast and Valuation - The company is expected to achieve net profits of 519 million RMB, 746 million RMB, and 1.077 billion RMB for the years 2024, 2025, and 2026, respectively, with corresponding year-on-year growth rates of 29%, 44%, and 44% [6]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 1.83 RMB, 2.63 RMB, and 3.80 RMB, with price-to-earnings (P/E) ratios of 19, 13, and 9 times, respectively [6].

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company reported a revenue of 3.501 billion RMB in Q3 2024, representing a year-on-year increase of 45.23%. The net profit attributable to shareholders was 332 million RMB, up 22.58% year-on-year [3]. - In Q3 2024, the company achieved a single-quarter revenue of 1.649 billion RMB, a 54.63% increase year-on-year, with a net profit of 227 million RMB, reflecting an 87.72% year-on-year growth [3]. - The company has a robust order backlog, with non-equipment orders increasing by 83% year-on-year, indicating a significant shift in product and order structure [4]. - The issuance of convertible bonds aims to raise up to 1.102 billion RMB for expanding electronic materials production and developing biopharmaceutical core equipment [5]. - The company completed a share buyback of 1,615,286 shares, representing 0.56% of total shares, demonstrating confidence in long-term growth [5]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a revenue of 3.501 billion RMB, with a net profit of 332 million RMB, marking significant growth compared to the previous year [3]. - The company expects to achieve net profits of 519 million RMB, 746 million RMB, and 1.077 billion RMB for the years 2024, 2025, and 2026, respectively, with corresponding growth rates of 29%, 44%, and 44% [6]. Operational Analysis - The company has optimized its sales layout in domestic and international markets, with non-equipment business development accelerating, now accounting for over 38% of new contracts [4]. - The operating cash flow for Q3 2024 was 240 million RMB, a 107% increase year-on-year, indicating improved collection efficiency [4]. Valuation Metrics - The expected earnings per share (EPS) for 2024, 2025, and 2026 are projected to be 1.83 RMB, 2.63 RMB, and 3.80 RMB, respectively, with price-to-earnings (P/E) ratios of 19, 13, and 9 [6].

Financial Performance - The company's operating revenue for Q3 2024 reached ¥1,649,089,360.52, representing a year-on-year increase of 54.63%[2] - Net profit attributable to shareholders for the same period was ¥226,709,328.81, an increase of 87.72% compared to the previous year[2] - The net profit excluding non-recurring gains and losses was ¥195,015,617.36, up 55.63% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.80, an increase of 81.82% year-on-year[3] - The diluted earnings per share for the same period was also ¥0.80, reflecting an increase of 86.05% compared to the previous year[3] - The net profit for Q3 2024 reached CNY 365,692,011.23, an increase from CNY 289,275,361.24 in Q3 2023, representing a growth of approximately 26.5%[22] - The total operating profit for Q3 2024 was CNY 368,396,665.32, compared to CNY 304,262,933.15 in the same period last year, indicating a year-over-year increase of about 20.9%[22] - The total revenue from sales of goods and services for the first three quarters of 2024 was CNY 2,577,098,727.34, compared to CNY 2,458,248,727.89 in the same period of 2023, reflecting a growth of approximately 4.8%[24] - The company's net profit attributable to shareholders for the first three quarters of 2024 was CNY 1,284,736,632.67, compared to CNY 1,034,022,224.78 in 2023, showing an increase of about 24.2%[20] Research and Development - Research and development expenses totaled ¥95,673,544.89 in Q3 2024, reflecting a 42.19% increase from the same period last year[3] - Research and development expenses for the first three quarters of 2024 amounted to CNY 251,842,036.41, up from CNY 151,291,501.40 in 2023, reflecting a growth of approximately 66.6%[21] - The proportion of R&D expenses to operating revenue was 5.80%, a decrease of 0.51 percentage points year-on-year[3] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,309,799,257.68, a 15.43% increase from the end of the previous year[3] - The company's total assets as of the end of the reporting period were CNY 9,309,799,257.68, compared to CNY 8,065,228,289.12 at the same time last year, marking an increase of about 15.4%[20] - The total liabilities of the company reached CNY 5,824,764,473.32, up from CNY 5,010,697,923.35 in the previous year, which is an increase of approximately 16.2%[20] - The company's total equity attributable to shareholders reached CNY 3,321,487,848.56, compared to CNY 3,001,886,794.49 in the previous year, indicating an increase of about 10.7%[20] Cash Flow - The cash flow from operating activities for the year-to-date period showed a decrease of 58.18%, totaling ¥117,396,446.55[2] - The company's cash flow from operating activities for the first three quarters of 2024 was CNY 117,396,446.55, down from CNY 280,718,174.12 in the previous year[26] - The company reported a net cash inflow from financing activities of CNY 721,575,904.20 in Q3 2024, a significant improvement compared to a net outflow of CNY 317,582,642.44 in Q3 2023[27] - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 853,003,341.19, slightly down from CNY 855,848,660.37 at the end of Q3 2023[27] - The cash and cash equivalents at the end of the reporting period were CNY 1,284,736,632.67, compared to CNY 1,034,022,224.78 in the previous year, indicating a growth of approximately 24.2%[20] - The company reported a significant increase in investment cash inflows, totaling CNY 716,907,411.42 in Q3 2024, compared to CNY 631,746,786.34 in Q3 2023, reflecting a growth of approximately 13.5%[26] Business Operations - Revenue for the first three quarters of 2024 increased by 45% compared to the same period last year[13] - The company’s accounts receivable grew by 25% year-over-year, significantly lower than the revenue growth, indicating improved collection efficiency[13] - New contracts for non-equipment business segments (including components, modules, gases, and advanced materials) increased by 83% year-over-year[13] - The company’s order backlog remains strong, with the IC industry accounting for approximately 50% of its business[13] - The proportion of new contracts from non-equipment business has exceeded 38%, reflecting a significant shift in the company’s product and business structure[13] - The company will no longer disclose detailed information on new contracts to avoid misleading investors regarding performance[13] Shareholder Actions - The company plans to issue convertible bonds with a total fundraising amount not exceeding RMB 1.15 billion, currently under review by the Shanghai Stock Exchange[13] - The company completed a share buyback of 938,229 shares for a total amount of RMB 30.15 million, representing 0.33% of the total share capital[14] - A second share buyback was completed, acquiring 1,615,286 shares for RMB 49.99 million, accounting for 0.56% of the total share capital[14] Foreign Exchange and Other Income - The company experienced a foreign exchange loss of CNY 7,419,339.93 in Q3 2024, compared to a gain of CNY 3,780,653.35 in Q3 2023[27] - The total comprehensive income for Q3 2024 was CNY 365,616,912.32, compared to CNY 290,821,612.17 in Q3 2023, showing an increase of approximately 25.7%[23]